24 June, 2024 | Monday
BioPharma Boardroom
Astellas and Roche Diabetes Care Japan Join Forces to Develop and Commercialize BlueStar®, an Integrated Diabetes Self-Management Solution

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that it has entered into an agreement ("the Agr...

March 29, 2023 | Wednesday | News
Cellusion Transplants First iPSC-Derived Corneal Endothelial Cell Substitute (CLS001) in Patient

Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., "Cellusion") announced that our research collaborator, Dr. Shigeto Shimmura, Professor of Fujita Health Univer...

March 28, 2023 | Tuesday | News
Incyte's Pemazyre® (pemigatinib) Approved in Japan for Myeloid/Lymphoid Neoplasms (MLNs)

ncyte (Nasdaq:INCY) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre® (pemigatinib), a selective fi...

March 28, 2023 | Tuesday | News
Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas

Sandoz plans to acquire worldwide product rights for Mycamine® (micafungin sodium) from Astellas Acquiring leading global echinocandin, one of three...

January 24, 2023 | Tuesday | News

Partner Content

BioPharma BreakThrough's

Editor Picks

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
  View poll results   More polls
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
BioPharma Boardroom

About Us Media Pack Contact Us Privacy Policy

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close